| |
Thursday, November 10, 2022 | 11am ET / 8am PT This webinar will cover compaction simulation and discrete element methods, tools that can improve product quality, expedite formulation and the case studies that demonstrate these capabilities. Register now.
|
|
|
Wednesday, November 30, 2022 | 11am ET / 8am PT In this webinar, we will show how data centricity, digitalization and automation streamlines CMC content authoring and why it is the most viable solution to tackle the associated challenges. Register now.
|
|
| By Nick Paul Taylor Eli Lilly is plowing a further $50 million into its research collaboration with Purdue University, signing up to work with its partner for another five years on challenges including intrathecal and nanoparticle drug delivery. |
|
|
|
By Nick Paul Taylor VacV Biotherapeutics has taken early steps toward the validation of its systemically deliverable Vaccinia virus, exiting stealth with $3 million to complete preclinical studies of its cancer immunotherapies. |
By Nick Paul Taylor Specialty pharma company Assertio Holdings has expanded its portfolio through a deal with Aquestive Therapeutics, paying $9 million upfront for exclusive rights to the Sympazan oral film formulation. |
By Nick Paul Taylor Researchers have turned to drug delivery nanoparticles to maximize the anti-cancer STING of a molecule, pointing to a possible way to unlock the potential of a pathway that has caught the eye of the industry. |
|
Tuesday, November 29th, 2022 | 10am ET / 7am PT / 4pm CET Join our webinar to learn more on this fascinating topic where our experts will share their experiences and challenges in getting a repurposed drug to market successfully. The webinar will review case studies of successful drug repositioning to the nose to more intuitive and user friendly drug delivery. Register Now.
|
|
By Kevin Dunleavy Nearly two years after shelling out $1.4 billion for MYR and its hepatitis D drug , Gilead has yet to gain sanction for bulevirtide in the U.S., and it’s not happening any time soon as the FDA has given it a thumbs down. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we dig into rumors of a shaky relationship between Biogen and Eisai. We also chat about AZ’s ability to finally tout the approval of an asset that’s seen many failures over the years. |
|
|---|
|
|
|
This playbook looks at why insolubility is an issue, and the properties that affect solubility, such as the molecule’s structure; its physical attributes (particle size and dissolution rate); its chemical attributes, including compatibility with excipients; and its biological properties. Download now.
|
|
| Webinar‘The Launch Rollercoaster: Riding the Highs and Lows’ webinar will include insights and strategies from HCPs and cross-functional launch experts. Grab your virtual seat to learn about the common challenges and tap into actionable learnings to drive launch success. Presented by: Lumanity | Thursday, November 15, 2022 2.00 PM GMT / 9.00 AM EST |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| |
|
